Skip to main content
Figure 5 | BMC Immunology

Figure 5

From: Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases

Figure 5

Effect of rhC2 on deposition of C3 fragment on the surface of Streptococcus pneumoniae analyzed by flow cytometry. The bacteria were incubated with C2 deficient (C2D) serum from patients, C2D serum with (25 μg/ml) rhC2 or plasma purified C2. Pooled normal human serum (NHS) was used as control. A) Results with 3 different C2D sera expressed as mean fluorescence index (MFI) ratio between the recorded fluorescence with anti-C3d antibody and the fluorescence obtained with the isotype control antibody. B) Flow cytometry plots showing MFI of C3 fragment deposition with one C2D serum (C2D-3) before and after restitution with rhC2.

Back to article page